FIGARO: Where will finerenone fit into diabetic kidney disease treatment | David Wheeler

David Wheeler talks about the findings of the FIGARO trial, the use of finerenone in people with type 2 diabetes, and how this may fit with SGLT2 inhibitors (7:22).

View more on Medicine Matters diabetes: https://diabetes.medicinematters.com/ and remember to Like this video and Subscribe to our channel

Diabetesfinerenonenephropathy